Evolus (EOLS) vs Evotec (EVO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evolus (EOLS) has outperformed Evotec (EVO) over the past year, gaining 23.6% versus a loss of 58.9%. Over five years, EOLS leads with a +0.9% price change compared with -92.9% for EVO. Evotec is the larger company by market cap ($572.2 million vs $511.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EOLS | EVO |
|---|---|---|
| Share price | $7.74 | $1.61 |
| Market cap | $511.23M | $572.18M |
| 1-day change | +4.88% | -1.23% |
| YTD return | +16.39% | -47.73% |
| 1-year return | +23.64% | -58.93% |
| 5-year return | +0.91% | -92.87% |
| Forward P/E | 26.46 | — |
| EPS (TTM) | $-0.56 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.31 | $4.27 |
| 52-week low | $3.86 | $1.50 |
| Distance from 52-week high | -16.86% | -62.30% |
| Analyst consensus | none | none |
| Avg. price target upside | +93.80% | +158.39% |
| Average volume | 901.46K | 104.15K |
| Shares outstanding | 66.05M | 355.39M |
| Employees | 353 | 4,461 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EOLS has outperformed EVO by 82.6 percentage points over the past year.
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Healthcare · Drug Manufacturers - Specialty & Generic · 353 employees
About Evotec
EVO stock →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Healthcare · Drug Manufacturers - Specialty & Generic · 4,461 employees
EOLS vs EVO FAQ
Which is bigger, Evolus or Evotec?
Evotec (EVO) is larger, with a market capitalization of $572.18M compared with $511.23M for Evolus (EOLS).
Which stock has performed better over the past year, EOLS or EVO?
EOLS returned +23.64% over the past 12 months, compared with -58.93% for EVO (price return, excluding dividends). Past performance does not predict future results.
Are Evolus and Evotec in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.